Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F19%3A00007993" target="_blank" >RIV/00023884:_____/19:00007993 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10384268
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505445/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505445/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/neuros/nyy178" target="_blank" >10.1093/neuros/nyy178</a>
Alternative languages
Result language
angličtina
Original language name
Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study
Original language description
BACKGROUND Stereotactic radiosurgery (SRS) is a treatment option for persistent or recurrent acromegaly secondary to a growth hormone secreting pituitary adenoma, but its efficacy is inadequately defined. OBJECTIVE To assess, in a multicenter, retrospective cohort study, the outcomes of SRS for acromegaly and determine predictors. METHODS We pooled and analyzed data from 10 participating institutions of the International Gamma Knife Research Foundation for patients with acromegaly who underwent SRS with endocrine follow-up of 6 mo. RESULTS The study cohort comprised 371 patients with a mean endocrine follow-up of 79 mo. IGF-1 lowering medications were held in 56% of patients who were on pre-SRS medical therapy. The mean SRS treatment volume and margin dose were 3.0 cm(3) and 24.2 Gy, respectively. The actuarial rates of initial and durable endocrine remission at 10 yr were 69% and 59%, respectively. The mean time to durable remission after SRS was 38 mo. Biochemical relapse after initial remission occurred in 9%, with a mean time to recurrence of 17 mo. Cessation of IGF-1 lowering medication prior to SRS was the only independent predictor of durable remission (P = .01). Adverse radiation effects included the development of 1 new endocrinopathy in 26% and 1 cranial neuropathy in 4%. CONCLUSION SRS is a definitive treatment option for patients with persistent or recurrent acromegaly after surgical resection. There appears to be a statistical association between the cessation of IGF-1 lowering medications prior to SRS and durable remission.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neurosurgery
ISSN
0148-396X
e-ISSN
—
Volume of the periodical
84
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
717-724
UT code for WoS article
000460636600067
EID of the result in the Scopus database
2-s2.0-85061582570